Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia

Br J Haematol. 2011 Feb;152(4):365. doi: 10.1111/j.1365-2141.2010.08481.x. Epub 2010 Dec 1.

Authors

Patrizia Suppressa¹, Arcangelo Liso, Carlo Sabbà

Affiliation

¹ Unit of Geriatrics and Gerontology and Rare Diseases, Department of Internal Medicine and Public Health, University of Bari, Polyclinic, Bari, Italy.

PMID: 21265821
DOI: 10.1111/j.1365-2141.2010.08481.x

No abstract available

Publication types

Case Reports

MeSH terms

Anemia / etiology
Anemia / prevention & control*
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Drug Administration Schedule
Facial Dermatoses / drug therapy*
Humans
Male
Middle Aged
Telangiectasia, Hereditary Hemorrhagic / complications
Telangiectasia, Hereditary Hemorrhagic / drug therapy*

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab